Spadek masy ciała o 19,3% po 48 tygodniach: na EASD zaprezentowano dane III fazy dotyczące olatorepatydu - agonisty receptorów GLP-1/GIP firmy Hansoh o ukierunkowanej sygnalizacji w obu receptorach

Hansoh Pharma's GLP-1 receptor agonist was referenced in connection with the European Association for the Study of Diabetes (EASD) annual meeting in Milan, held September 28 to October 2, 2026. The provided article excerpt contains no clinical efficacy, safety, regulatory, commercial, or financial data, limiting its immediate investment significance.